Adverse events with Zyban (buproprion) [2]

CMAJ. Canadian Medical Association Journal

Volumn 169, Issue 2, 2003, Pages 103-104

  Kolber, Michael ^a   Spooner, G Richard ^a   Szafran, Olga ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE;

AGITATION; CANADA; CLINICAL PRACTICE; COMMUNITY CARE; CONFUSION; DEATH; HUMAN; INSOMNIA; LETTER; MEDICAL CARE; MEDICAL LITERATURE; PHYSICIAN; PRESCRIPTION; PROSPECTIVE STUDY; RASH; SMOKING CESSATION; TREMOR; UNITED KINGDOM; NOTE;

BUPROPION; HUMANS; SMOKING CESSATION;

EID: 0043201347     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Mintzes B, Bassett K, Wright JM. Drug safety without borders: concerns about buproprion [letter]. CMAJ 2002;167(5):447.
2. Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale JC, et al. A comparison of sustained-release buproprion and placebo for smoking cessation. N Engl J Med 1997;337(17): 1195-202.
3. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, et al. A controlled trial of sustained-release buproprion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999;340(9):685-91.